focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,775.00
Bid: 1,771.00
Ask: 1,771.50
Change: -8.50 (-0.48%)
Spread: 0.50 (0.028%)
Open: 1,773.50
High: 1,779.00
Low: 1,764.50
Prev. Close: 1,783.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 1-European stocks slip after four-day run, U.S. tariffs hit Airbus

Thu, 13th Aug 2020 09:39

(For a live blog on European stocks, type LIVE/ in an Eikon
news window)

* FTSE 100 leads declines on ex-dividend trading

* Investors confident of imminent U.S. stimulus - analysts

* Thyssenkrupp slides on flagging losses in steel unit

* Danish brewer Carlsberg falls on sales warning in key
markets
(Adds comments; updates prices)

By Sruthi Shankar and Sagarika Jaisinghani

Aug 13 (Reuters) - European stocks fell on Thursday as
simmering tensions between the United States and China, and
elusive U.S. fiscal stimulus, pushed investors to book profits
after four straight sessions of gains, while Airbus dipped as
Washington left aircraft tariffs unchanged.

The pan-European STOXX 600 was off 0.4%, with
Airbus sliding 1.2% after the U.S. government said it
would maintain 15% tariffs on planes and 25% tariffs on other
European goods, despite moves to resolve a long-standing dispute
over aircraft subsidies.

London's FTSE 100 was at the front of declines among
major European bourses, led by AstraZeneca, BP,
Diageo, Glaxosmithkline and Legal&General
, which traded without entitlement to a dividend payout.

Still, with the U.S. S&P 500 index within striking
distance of a record high, analysts said there were few cues for
global equities to pull back, with investors also disregarding
U.S-China angst.

"There's no stopping this market at the moment," said
Michael Baker, an analyst at ETX Capital.

"There's not a lot negative sentiment (and) the market is
fairly confident that a U.S. stimulus deal will be reached even
if it's a last minute one."

U.S. Democrats and Republicans remain deadlocked after weeks
of wrangling over a fifth coronavirus aid bill. President Donald
Trump on Wednesday accused congressional Democrats of not
wanting to negotiate because he was refusing to go along with
"ridiculous" spending requests unrelated to the pandemic.

In Europe, the STOXX 600 is still about 14% below its
all-time high as data points to a slower-than-expected rebound
from the pandemic. A survey on Thursday showed German companies
expect business to return to normal in an average of 11 months,
with the number even higher for firms in the services sector.

Struggling conglomerate Thyssenkrupp plunged 13.1%
after it said its steel unit would rack up 1 billion euros ($1.2
billion) in operating losses this year, raising pressure to fix
or sell the division. The stock is on course for its biggest
one-day decline in three months.

Danish brewer Carlsberg slid 4.7% on warning that
lockdowns will impact sales in the second half of the year in
its key markets of China and Western Europe.

TUI, the world's largest tourism company, fell 3.0%
as it sunk to a 1.1 billion euro ($1.30 billion) loss in the
third quarter due to the COVID-19 pandemic.
(Reporting by Sruthi Shankar in Bengaluru; Additional reporting
by Sagarika Jaisinghani; Editing by Arun Koyyur, Bernard Orr)

More News
17 Jan 2024 07:31

GSK raises $1.24 bln from latest Haleon stake sale

Jan 17 (Reuters) - GSK has raised 978 million pounds ($1.24 billion) from a discounted sale of a stake in its spun-off consumer healthcare business Haleon, the British drugmaker said on Wednesday.

Read more
16 Jan 2024 17:04

GSK to sell GBP1 billion worth of Haleon shares as trims stake again

(Alliance News) - GSK PLC on Tuesday said it intends to sell around GBP1.00 billion worth of shares in Haleon PLC, as it continues to reduce its shareholding in the Weybridge, Surrey-based consumer healthcare spin-off.

Read more
16 Jan 2024 09:14

LONDON BROKER RATINGS: UBS raises GSK and cuts AstraZeneca

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
16 Jan 2024 08:15

UBS downgrades AstraZeneca to 'sell'

(Sharecast News) - UBS has downgraded AstraZeneca and upgraded rival GSK as part of its latest review of the European pharmaceutical sector.

Read more
16 Jan 2024 07:37

LONDON BRIEFING: UK jobless rate sticks at 4.2% but pay growth slows

(Alliance News) - Stocks in London are called to open lower on Tuesday, following data showing that the UK jobless rate was unchanged at 4.2% as pay growth slowed.

Read more
15 Jan 2024 08:42

Zantac fallout unfairly weighing on GSK, says Shore Capital

(Sharecast News) - Shore Capital has raised its target price and maintained a positive stance on biopharma giant GSK, saying that worries about the potential cost of Zantac litigation are unfairly weighing on the stock.

Read more
10 Jan 2024 09:35

LONDON BROKER RATINGS: BofA cuts Ashtead; UBS likes 3i Group

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
10 Jan 2024 08:25

GSK says Nucala gets green light in China for asthma treatment

(Alliance News) - GSK PLC on Wednesday said Nucala has been approved in China for the treatment of severe asthma.

Read more
10 Jan 2024 07:22

GSK's Nucala gets fresh approval in China

(Sharecast News) - GSK announced on Wednesday that the China National Medical Products Administration (NMPA) has granted approval for 'Nucala', or mepolizumab, as an add-on maintenance treatment for severe eosinophilic asthma in adults and adolescents aged 12 years and older.

Read more
9 Jan 2024 16:22

London close: Stocks finish red after choppy session

(Sharecast News) - London stocks had turned back into the red by the close on Tuesday, with recruitment firms and asset managers pacing the declines after some disappointing corporate updates.

Read more
9 Jan 2024 08:03

TOP NEWS: GSK to buy Aiolos Bio for up to USD1.4 billion

(Alliance News) - GSK PLC on Tuesday said it will acquire asthma drug developer Aiolos Bio Inc for USD1 billion upfront, as well as up to USD400 million in certain success-based milestone payments.

Read more
9 Jan 2024 07:16

GSK buys respiratory drug maker Aiolos for $1bn

(Sharecast News) - GSK said it was buying Aiolos, a clinical-stage biopharmaceutical company focused on treatment of respiratory and inflammatory conditions, for up to $1.4bn (£1.1bn).

Read more
8 Jan 2024 23:39

Pfizer to remain aggressive on obesity market after setback

NEW YORK, Jan 8 (Reuters) - Pfizer will remain aggressive in trying to break into the lucrative obesity market, even after dropping a high profile weight-loss drug candidate late last year due to strong side effects, Chief Executive Albert Bourla said on Monday.

Read more
8 Jan 2024 23:00

Pfizer to remain aggressive on obesity market after setback

NEW YORK, Jan 8 (Reuters) - Pfizer will remain aggressive in trying to break into the lucrative obesity market, even after dropping a high profile weight-loss drug candidate late last year due to strong side effects, Chief Executive Albert Bourla said on Monday.

Read more
8 Jan 2024 19:02

Moderna says it hit its 2023 COVID vaccine sales goal

Jan 8 (Reuters) - Moderna on Monday said its 2023 COVID vaccine sales would be around $6.7 billion, coming in above the lower end of its full-year forecast, and reiterated its goal of returning to sales growth in 2025.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.